Guangdong Zhongke Pharmaceutical Research Co., Ltd.，Established in 2005 and headquartered at the Guangzhou International Business Incubator, Guangdong Zhongke Pharmaceutical Research Co., Ltd. is a high-tech enterprise and a Guangdong Provincial "Specialized, Refined, Distinctive, and Innovative" (专精特新) company dedicated to the research and development of small-molecule chemical innovative drugs. With a strong commitment to addressing unmet clinical needs, the company has positioned itself as a leader in patent technology transfers within China’s pharmaceutical innovation sector.

Achievements & Expertise

The company has undertaken and completed 2 National Major New Drug Innovation Projects, jointly accomplished 2 additional National Major New Drug Innovation Projects, and spearheaded the groundbreaking project "GPCR Structure-Based Drug Innovation" in collaboration with the Shanghai Institute of Materia Medica (Chinese Academy of Sciences), Peking University, and other institutions in 2016. It has also executed 2 Guangdong Provincial Major Science & Technology Projects, 2 Guangzhou Municipal Key Science & Technology Projects, and 1 National Innovation Fund. To date, the company holds over 30 authorized patents, secured 3 Category 1.1 New Drug Clinical Approvals, and transferred 4 Class 1 New Drug Achievements, including a cumulative patent transfer value of RMB 171 million.

Founder Profile

The company was founded by Mr. Wang Wei, a Master of Pharmacy, Associate Chief Pharmacist, and recognized expert in Guangdong and Guangzhou municipal science and technology project evaluations. As a distinguished high-level talent in Guangzhou, Mr. Wang’s leadership has driven the company’s innovative vision and scientific rigor.

Pipeline Highlights

Binaprofen Injection (Category 1.1)

Indication: Cancer and postoperative pain relief.

Transferred in 2012 for RMB 48 million, this drug has completed Phase III trials, demonstrating superior safety and efficacy compared to first-line therapies. Poised for production approval and New Drug Certificate (NDA) submission, it holds authorized patents in China and the U.S.

ZONK1103 (XY-03, Category 1)

Indication: Stroke treatment.

Transferred for RMB 38 million, this drug outperforms the reference drug Butylphthalide in safety and pharmacodynamics. Phase II trials confirm its advantages over the leading drug Edaravone, with patents already granted.

Binaprofen Eye Drops (Category 1.1)

The first Category 1.1 ophthalmic formulation in China to receive clinical approval (2016). Backed by PCT international patents and RMB 25 million + 50% equity financing agreements (2018), it is currently in Phase II trials after securing provincial and municipal R&D grants.

ZONK1901 (Category 1.1)

A multi-target inhibitor for prostate cancer, positioned as a First-in-Class (FIC) and Best-in-Class (BIC) candidate. It addresses drug resistance issues in existing therapies and exhibits exceptional pharmacodynamic advantages.

ZONK2301

Targets liver and pulmonary fibrosis with a novel structural design distinct from Pirfenidone. Demonstrates superior efficacy and safety in preclinical pulmonary fibrosis models, with ongoing liver fibrosis studies. Domestic and PCT patents are pending.

Vision

Guangdong Zhongke Pharmaceutical Research Co., Ltd. prioritizes pioneering structural innovation and clinical necessity over imitation, aiming to solidify its leadership in domestic patent technology transfers while expanding globally. The company’s long-term vision is to achieve international recognition through transformative drug discovery and strategic partnerships, advancing therapies that redefine treatment paradigms.

This concise yet comprehensive profile underscores the company’s scientific excellence, commercialization capabilities, and ambition to bridge innovation with global healthcare solutions.